Phibro Animal Health (PAHC)
(Delayed Data from NSDQ)
$19.42 USD
-0.23 (-1.17%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $19.43 +0.01 (0.05%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
Phibro Animal Health (PAHC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$14.00 | $19.00 | $9.00 | -28.75% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Phibro Animal Health comes to $14.00. The forecasts range from a low of $9.00 to a high of $19.00. The average price target represents a decline of 28.75% from the last closing price of $19.65.
Analyst Price Targets (4 )
Broker Rating
Phibro Animal Health currently has an average brokerage recommendation (ABR) of 4.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 4.25 a month ago based on four recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 4.25 | 4.25 | 4.25 | 4.25 | 4.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/10/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
12/7/2023 | Exane BNP Paribas | Research Department | Not Available | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 4.25 |
ABR (Last week) | 4.25 |
# of Recs in ABR | 4 |
Average Target Price | $14.00 |
LT Growth Rate | 8.70% |
Industry | Medical - Products |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | 0.23 |